Sort by:

• Highly Influential Citations
• Citations
• Acceleration
• Velocity
• Recency

Learn More

Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade

• Martina Schmittnaegel, Nicolò Rigamonti, +8 authors Michele De Palma
• Science Translational Medicine
• 2017

Pathological angiogenesis is a hallmark of cancer and a therapeutic target. Vascular endothelial growth factor A (VEGFA) and angiopoietin-2 (ANGPT2; also known as ANG2) are proangiogenic cytokines… (More)

Suppression of microRNA activity amplifies IFN-γ-induced macrophage activation and promotes anti-tumour immunity

• Caroline Baer, Mario Leonardo Squadrito, +7 authors Michele De Palma
• Nature Cell Biology
• 2016

Tumour-associated macrophages (TAMs) largely express an alternatively activated (or M2) phenotype, which entails immunosuppressive and tumour-promoting capabilities. Reprogramming TAMs towards a… (More)

Macrophage Susceptibility to Emactuzumab (RG7155) Treatment.

• Leon P. Pradel, Chia-Huey Ooi, +4 authors Carola H Ries
• Molecular cancer therapeutics
• 2016

Blockade of colony-stimulating factor-1 receptor (CSF-1R) enables the therapeutic targeting of tumor-associated macrophages (TAM) in cancer patients. Various CSF-1R inhibitors, mAbs, and tyrosine… (More)

The gene signature in CCAAT-enhancer-binding protein α dysfunctional acute myeloid leukemia predicts responsiveness to histone deacetylase inhibitors.

• Adam Liss, Chia-Huey Ooi, +10 authors Meritxell Alberich-Jordà
• Haematologica
• 2014

C/EPBα proteins, encoded by the CCAAT-enhancer-binding protein α gene, play a crucial role in granulocytic development, and defects in this transcription factor have been reported in acute myeloid… (More)

Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity

• Sabine Hoves, Chia-Huey Ooi, +15 authors Carola H Ries
• The Journal of experimental medicine
• 2018

Depletion of immunosuppressive tumor-associated macrophages (TAMs) or reprogramming toward a proinflammatory activation state represent different strategies to therapeutically target this abundant… (More)

Tissue-Specific Immunoregulation: A Call for Better Understanding of the "Immunostat" in the Context of Cancer.

• William Pao, Chia-Huey Ooi, +9 authors John C. Reed
• Cancer discovery
• 2018

Checkpoint inhibitor therapy has been a breakthrough in cancer research, but only some patients with cancer derive substantial benefit. Although mechanisms underlying sensitivity and resistance to… (More)

Evaluation of efficacy of a new MEK inhibitor, RO4987655, in human tumor xenografts by [18F] FDG-PET imaging combined with proteomic approaches

• T Tegnebratt, Elisabeth Ruge, +12 authors Sharon Stone-Elander
• EJNMMI research
• 2014

BACKGROUND Inhibition of mitogen-activated protein kinase (MEK, also known as MAPK2, MAPKK), a key molecule of the Ras/MAPK (mitogen-activated protein kinase) pathway, has shown promising effects on… (More)

• ‹
• 1
• ›